AUS
NZ
UK
CA
USA
IND
Healthcare
FTSE 100 Pharma Strength As AstraZeneca Drives Momentum
April 29, 2026 10:26 AM BST| By Vivek SinghHealthcare sector strength, led by AstraZeneca, reflects stability and innovation within the FTSE market, highlighting the role of pharmaceutical companies in shaping UK equity performance.
FTSE 100 Healthcare Strength As GSK Drives Market Momentum
April 29, 2026 10:06 AM BST| By Vivek SinghHealthcare sector strength, led by pharmaceutical companies, continues to shape FTSE performance, reflecting stability and innovation within the UK equity market.
FTSE 350: Is Genflow Drawing Interest After Canine Gene Data?
April 28, 2026 02:07 PM BST| By Vivek SinghGenflow Biosciences broadens collaboration efforts in the FTSE 350, highlighting growing interest in canine gene therapy research and continued progress in ageing-related biotechnology studies.
AOTI Strengthens on Wound Therapy Outcomes
April 27, 2026 05:52 PM BST| By Vivek SinghHighlights,Wound oxygen therapy shows strong clinical outcomes in chronic care,Real-world study highlights improved healing in complex wound cases,Reduced complications observed compared with conventional treatment approaches,AOTI shares moved higher...
FTSE 350 GSK PLC Oncology Court Ruling Drives Legal Case Progress?
April 27, 2026 02:31 PM BST| By Vivek SinghGSK PLC within the FTSE 350 reflects ongoing legal proceedings, oncology portfolio expansion, and pharmaceutical sector activity centred on dostarlimab development and licensing frameworks.
AstraZeneca PLC FTSE 100 reacts to partner review delay results?
April 27, 2026 02:31 PM BST| By Vivek SinghAstraZeneca activity in the FTSE 100 highlights oncology partnerships, manufacturing adjustments, and structured collaboration within global pharmaceutical development and supply chain systems.
AstraZeneca Outlook Steady Amid Daiichi Review Update
April 27, 2026 12:18 PM BST| By Vivek SinghAstraZeneca outlook remains steady after Daiichi Sankyo supply review update, with oncology partnerships continuing smoothly and market interpretation pointing to operational adjustments without disruption to core pharmaceutical collaboration.
Does GSK’s FTSE 100 Standing Shift After Court Claim Dismissal?
April 27, 2026 11:46 AM BST| By Vivek SinghGSK’s FTSE 100 presence reflects ongoing legal and clinical developments, including a narrowed dispute over a cancer drug licence and continued research into oncology treatments.
FTSE Megatrends: Where Future Market Leaders Begin
April 24, 2026 01:30 PM BST| By Team Kalkine MediaMegatrends are reshaping global markets, offering insights into future leaders. Understanding thematic strategies, stock selection, and index performance is key to navigating long-term growth opportunities effectively.
AstraZeneca Advances Kidney Care With Ultomiris Breakthrough
April 22, 2026 05:53 PM BST| By Vivek SinghHighlights,Ultomiris shows strong progress in rare kidney condition study,Early signs indicate reduced kidney stress markers,Regulatory pathway discussions expected in key regions,AstraZeneca’s latest study highlights encouraging progress for a rare...
AstraZeneca Advances Kidney Care with Ultomiris Trial Success
April 21, 2026 08:52 PM BST| By Vivek SinghAstraZeneca reports encouraging trial progress for Ultomiris in rare kidney disease, supporting future regulatory submissions and expanding focus within the LSE & FTSE stock market landscape.
Hemogenyx Insider Activity Signals Long-Term Confidence
April 21, 2026 08:20 PM BST| By Vivek SinghInsider activity at Hemogenyx Pharmaceuticals highlights confidence, strong ownership alignment, and evolving trends within the UK equity market.
What is driving Sectra momentum?
April 21, 2026 05:00 PM BST| By Team Kalkine MediaSectra cloud agreement highlights healthcare technology expansion, collaborative NHS initiatives, and the growing role of digital imaging platforms shaping connected clinical environments across modern healthcare systems.
London Stocks Mixed as Pharma and Defence Weigh
April 21, 2026 01:07 PM BST| By Vivek SinghHighlights,London equities show mixed direction amid global cues,Defence and pharmaceutical names face selling pressure,Real estate and consumer sectors provide selective support,London equity markets have reflected a mixed tone as global macroeconom...
AstraZeneca Drug Advances Spark Strong Market Attention
April 21, 2026 12:25 PM BST| By Vivek SinghHighlights,Late-stage trials reinforce confidence in respiratory therapy,Expanded patient scope opens wider commercial pathway,Market outlook aligns with strong long-term revenue expectations,AstraZeneca’s latest clinical progress in respiratory trea...
IXICO’s Momentum Builds as Growth Strategy Gains Ground
April 21, 2026 11:55 AM BST| By Vivek SinghIXICO’s growth story strengthens with rising demand, expanding order visibility, and strategic investment aimed at broadening its reach across clinical trials and healthcare ecosystems.
IXICO’s Growth Path: TechBio Strategy Gains Momentum
April 21, 2026 11:40 AM BST| By Vivek SinghIXICO advances its TechBio strategy with strong contract growth, expanding margins, and rising demand for CNS trial analytics, strengthening its long-term outlook in the clinical research space.
Chill Brands Restructure Plan Signals Strategic Shift Ahead
April 20, 2026 08:00 PM BST| By Vivek SinghHighlights,Shareholder meetings scheduled to clear pending matters,Capital reorganisation aims to reshape share structure,Move expected to support flexible future share issuance,Chill Brands Group is advancing a share capital overhaul alongside key s...
Genflow Biosciences Advances with Key RNA Collaboration
April 20, 2026 12:03 PM BST| By Vivek SinghHighlights,Major collaboration expands delivery technology access,Non-cash, non-dilutive structure supports development path,Research focus strengthened through advanced nanoparticle platform,Genflow Biosciences strengthens its research and developme...
Genflow Biosciences FTSE 350 Biotech Shares Rise on New Deal?
April 20, 2026 12:03 PM BST| By Vivek SinghGenflow Biosciences highlights its FTSE 350 presence through collaboration, advancing gene therapy research and integrating delivery technologies in the biotechnology and healthcare innovation landscape.
